C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
6.45
+0.84 (14.97%)
At close: Nov 4, 2024, 4:00 PM
6.31
-0.14 (-2.17%)
After-hours: Nov 4, 2024, 7:38 PM EST
C4 Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for C4 Therapeutics stock have an average target of 10.5, with a low estimate of 6.00 and a high estimate of 20. The average target predicts an increase of 62.79% from the current stock price of 6.45.
Analyst Consensus: Buy
* Price targets were last updated on Aug 6, 2024.
Analyst Ratings
The average analyst rating for CCCC stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 4 | 4 | 4 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Reiterates $20 | Buy | Reiterates | $20 | +210.08% | Aug 6, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $7 → $8 | Hold | Maintains | $7 → $8 | +24.03% | May 9, 2024 |
| Stifel | Stifel | Strong Buy Maintains $13 → $14 | Strong Buy | Maintains | $13 → $14 | +117.05% | May 9, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $1 → $8 | Hold | Maintains | $1 → $8 | +24.03% | Feb 26, 2024 |
| Stifel | Stifel | Strong Buy Reiterates $12 → $13 | Strong Buy | Reiterates | $12 → $13 | +101.55% | Feb 23, 2024 |
Financial Forecast
Revenue This Year
29.00M
from 20.76M
Increased by 39.70%
Revenue Next Year
21.29M
from 29.00M
Decreased by -26.58%
EPS This Year
-1.50
from -2.67
EPS Next Year
-1.67
from -1.50
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 48.3M | 48.3M | 38.6M | ||
| Avg | 29.0M | 21.3M | 17.7M | ||
| Low | 14.7M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 132.7% | 66.6% | 81.5% | ||
| Avg | 39.7% | -26.6% | -16.9% | ||
| Low | -29.2% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.24 | -1.32 | -1.35 |
| Avg | -1.50 | -1.67 | -1.57 |
| Low | -1.67 | -2.31 | -2.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.